A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions.
In a small cohort of leukemic patients participating in a randomized trial of ABO-identical vs. ABO-unmatched platelet transfusions, a statistically significant decrease in remission duration and increase in mortality were observed in patients receiving ABO-unmatched platelet transfusions. This difference was unexplained by previously described prognostic factors for remission duration and survival. Further study of this association is warranted.